Neuropsychological Evaluation for Early Diagnosis of PSP
The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy
1 other identifier
observational
112
0 countries
N/A
Brief Summary
The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2016
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 2, 2018
CompletedFirst Submitted
Initial submission to the registry
March 20, 2018
CompletedFirst Posted
Study publicly available on registry
March 27, 2018
CompletedMarch 27, 2018
March 1, 2018
2.2 years
March 20, 2018
March 20, 2018
Conditions
Outcome Measures
Primary Outcomes (9)
MMSE
Mini-Mental State Examination
1 year
FAB
Frontal Assessment Battery
1 year
MoCA
Montreal Cognitive Assessment
1 year
WCST
Wisconsin Card Sorting Test
1 year
ST
Stroop Test
1 year
TMT-A and B
Trail Making Test Parts A \& B
1 year
VFT
Verbal fluency Test
1 year
ROCF copy and delayed recall
Rey-Osterrieth complex figure test copy and delayed recall
1 year
RAVLT
Rey Auditory Verbal Learning Test
1 year
Secondary Outcomes (3)
6MWT
1 year
TUG
1 year
BBS
1 year
Study Arms (2)
PSP patients
Patients suffering from Progressive Supranuclear Palsy (PSP)
PD Patients
Patients suffering from Parkinson's disease (PD)
Interventions
An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
Eligibility Criteria
56 PSP patients (PSPp) and 56 PD patients (PDp) were enrolled and matched for sex, age and disease duration.
You may qualify if:
- Patients fulfilling the criteria for idiopathic PD
- Patients fulfilling the criteria for PSP
You may not qualify if:
- Any other neurodegenerative disorders or medical conditions different from PD / PSP
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Giuseppe Frazzitta, MD
Department of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, "Moriggia-Pelascini" Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 20, 2018
First Posted
March 27, 2018
Study Start
January 1, 2016
Primary Completion
March 1, 2018
Study Completion
March 2, 2018
Last Updated
March 27, 2018
Record last verified: 2018-03